[A new microfilaricide in the therapeutic arsenal of the ophthalmologist].
With no doubt the Ophthalmologist in Tropical African country is the practician most needed for ocular disorders which are precursors of blindness by onchocerciasis or loasis. So, he has to be well-informed concerning each new product able to bring a better efficacy in the treatment of his patients suffering from one or two of these endemic filariasis. He has to know as well how to use it perfectly to experiment it if needed. Ivermectine, MECTIZAN patented, is nowadays the microfilariacide most tolerated in human medicine and is very easy to use in mass therapeutic campaigns as it is easy to administer: one oral dose is available for at least six months. This work deals with the structure of this new anti-parasitary, its quite particular action mechanism, its quite easy dosage, its use precautions and possible contraindications. By this, each practicioner has not to wait an important medical advertisement on this product which is being tested to know the basic points on it and to know how to get it for a possible experimentation for a point of information.
Toufic
N
N
D001766:Blindness / Q000517:prevention & control*; D005368:Filariasis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008118:Loiasis / Q000150:complications / Q000188:drug therapy; D009855:Onchocerciasis / Q000150:complications / Q000188:drug therapy
D007559:Ivermectin
Un nouveau microfilaricide dans l'arsenal thérapeutique de l'ophtalmologiste.